Neurocrine Biosciences, Inc. (LON:0K6R)
125.14
-11.32 (-8.29%)
Feb 12, 2026, 4:55 PM GMT
Neurocrine Biosciences Employees
Neurocrine Biosciences had 1,800 employees as of September 30, 2025. The number of employees increased by 100 or 5.88% compared to the same quarter last year.
Employees
1,800
Change
100
Growth
5.88%
Revenue / Employee
1.18M GBP
Profits / Employee
197.56K GBP
Market Cap
10.04B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 1,800 | 100 | 5.88% |
| Jun 30, 2025 | 1,800 | 300 | 20.00% |
| Mar 31, 2025 | 1,800 | 352 | 24.31% |
| Dec 31, 2024 | 1,800 | 400 | 28.57% |
| Sep 30, 2024 | 1,700 | 300 | 21.43% |
| Jun 30, 2024 | 1,500 | 150 | 11.11% |
| Mar 31, 2024 | 1,448 | 148 | 11.38% |
| Dec 31, 2023 | 1,400 | 200 | 16.67% |
| Sep 30, 2023 | 1,400 | 250 | 21.74% |
| Jun 30, 2023 | 1,350 | 250 | 22.73% |
| Mar 31, 2023 | 1,300 | 200 | 18.18% |
| Dec 31, 2022 | 1,200 | 300 | 33.33% |
| Sep 30, 2022 | 1,150 | 233 | 25.41% |
| Jun 30, 2022 | 1,100 | 216 | 24.43% |
| Mar 31, 2022 | 1,100 | 235 | 27.17% |
| Dec 31, 2021 | 900 | 55 | 6.51% |
| Sep 30, 2021 | 917 | 92 | 11.15% |
| Jun 30, 2021 | 884 | 104 | 13.33% |
| Mar 31, 2021 | 865 | 115 | 15.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,000 |
| Convatec Group | 10,000 |
| Hikma Pharmaceuticals | 9,500 |
| CVS Group | 8,850 |
| Genus | 3,190 |
Neurocrine Biosciences News
- 2 days ago - Preview: Neurocrine Biosciences's Earnings - Benzinga
- 6 days ago - Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS - Nasdaq
- 17 days ago - Neurocrine Biosciences (NBIX) Begins Phase 2 Trial for Tardive Dyskinesia Treatment - GuruFocus
- 17 days ago - Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia - PRNewsWire
- 20 days ago - NBIX Stock Rating Update: UBS Lowers Price Target to $178 | NBIX Stock News - GuruFocus
- 21 days ago - Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results - PRNewsWire
- 22 days ago - GraniteShares Advisors LLC Sells 3,122 Shares of Neurocrine Biosciences Inc (NBIX) - GuruFocus
- 22 days ago - BAM Wealth Management, LLC Buys 271 Shares of Neurocrine Biosciences Inc (NBIX) - GuruFocus